FDA Issues Complete Response Letter for Achieve Life Sciences' Cytisinicline, Spurring Manufacturing Transition to Adare
On June 22, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Achieve Life Sciences' New Drug Application (NDA) for cytisinicline—a plant-based alkaloid designed to bind to nicotinic acetylcholine receptors and aid in smoking and e-cigarette cessation.
Crucially, the FDA did not identify any deficiencies in clinical efficacy or safety, nor did it request new clinical trials. Instead, the CRL was triggered entirely by:
- Manufacturing Deficiencies: Outstanding cGMP observations from an inspection of a prior third-party manufacturing partner1, which had received an Official Action Indicated (OAI) classification for general facility issues unrelated to cytisinicline.
- Labeling: Incomplete final product labeling as of the agency's action date.
Achieve had anticipated this outcome and has already taken extensive corrective measures. The company has transitioned its primary manufacturing operations to Adare Pharma Solutions, a U.S.-based contract development and manufacturing organization. Achieve has already completed analytical method technology transfer, manufactured its first cytisinicline engineering batch, and qualified all testing procedures at the Adare facility.
Achieve plans to formally resubmit its NDA in Q4 2026 with Adare as its primary manufacturing partner, aiming for potential FDA approval in the first half of 2027. The clinical package remains highly robust, backed by the ORCA-2 and ORCA-3 Phase 3 trials (enrolling over 2,000 smokers) and the ORCA-OL open-label long-term safety study (enrolling 475 participants), which showed high rates of continuous abstinence, reduced cravings, and excellent tolerability.
-
An instance of Flawless clinical profiles cannot salvage a drug from manufacturing facility failures. — Achieve Life Sciences' clinically robust smoking cessation drug was blocked by an FDA rejection triggered entirely by facility deficiencies at its manufacturing partner. ↩︎